Short answer
SOLENO THERAPEUTICS INC (SLNO) filed an 8-K current report with the SEC on April 7, 2026 reporting Item 8.01 (Other Events). Voluntary withdrawal of EMA marketing application for VIOKAT, the European version of U.S.-marketed VYKAT XR.
SOLENO THERAPEUTICS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Voluntary withdrawal of EMA marketing application for VIOKAT, the European version of U.S.-marketed VYKAT XR
- Withdrawal removes the expected mid-2026 EMA decision and delays potential European commercialization
- Strategic decision preserves the option to re-engage regulators later through an appropriate pathway
- Near-term European expansion outlook weakened, with no assurance of future EMA re-engagement
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SOLENO THERAPEUTICS INC 8-K filings
Get the next SLNO 8-K as it lands
Follow SLNO for push alerts, or ask the research agent what this filing means.